RT Book, Section
A1 Teter, Christian J.
A1 Kando, Judith C.
A1 Wells, Barbara G.
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1165100575
T1 Major Depressive Disorder
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1165100575
RD 2024/04/19
AB Content  UpdateAugust  15,  2019Brexanolone  (Zulresso)  for  Treatment  of  Postpartum  Depression  in  Adult  Women:  Brexanolone  is  a  neuroactive  steroid  and  GABAA  receptor  modulator  approved  for  treatment  of  postpartum  depression  in  adult  women.  Results  of  one  phase  II  and  two  phase  III  randomized,  double-blind,  placebo-controlled  clinical  trials  provide  evidence  for  the  efficacy  and  safety  of  brexanolone  compared  to  placebo  as  evidenced  by  reduction  in  HAM-D  scores.  Brexanolone  carries  a  black  box  warning  for  excessive  sedation  and  sudden  loss  of  consciousness  and  is  only  available  via  REMS  program  restriction.  The  treatment  requires  a  60-hour  continuous  intravenous  infusion  that  is  expected  to  cost  $34,000;  these  factors  will  limit  brexanolone  use  to  a  select  population  of  women  with  postpartum  depression.